Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies
- PMID: 39232443
- DOI: 10.1016/j.currproblcancer.2024.101129
Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies
Abstract
Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.
Keywords: DOTATATE; NETs; dosimetry; somatostatin receptor; theranostics.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Theranostics in Neuroendocrine Tumors.Cancer J. 2024 May-Jun 01;30(3):185-193. doi: 10.1097/PPO.0000000000000723. Cancer J. 2024. PMID: 38753753 Review.
-
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Curr Oncol Rep. 2024 May;26(5):538-550. doi: 10.1007/s11912-024-01526-5. Epub 2024 Apr 6. Curr Oncol Rep. 2024. PMID: 38581469 Free PMC article. Review.
-
Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.PET Clin. 2014 Jan;9(1):83-90. doi: 10.1016/j.cpet.2013.08.015. PET Clin. 2014. PMID: 25029937 Review.
-
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215
-
Enhancing precision: A predictive model for 177Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative 68Ga-DOTATATE PET and clinicopathological biomarkers.Theranostics. 2024 Jun 11;14(9):3708-3718. doi: 10.7150/thno.98053. eCollection 2024. Theranostics. 2024. PMID: 38948061 Free PMC article.
Cited by
-
Advances in Molecular Imaging for Neuroendocrine Neoplasms.Cancers (Basel). 2025 Jun 17;17(12):2013. doi: 10.3390/cancers17122013. Cancers (Basel). 2025. PMID: 40563663 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
